Drug intelligence / Profile preview

Kan Jang

Development stage
Phase 3
Lead developer
Swedish Herbal Institute
Modality
Small Molecules
Administration
Oral
01

Overview

Kan Jang is a standardized herbal medicinal product composed of extracts from *Andrographis paniculata* (commonly known as "andrographis") and *Eleutherococcus senticosus* ("Siberian ginseng" or "eleuthero"), sometimes also including *Echinacea purpurea* and *Justicia adhatoda* depending on the formulation. It is primarily used for the relief of symptoms associated with viral respiratory tract infections such as the common cold, influenza, and mild COVID-19. The mechanism of action involves antiviral, immunomodulatory, and anti-inflammatory effects attributed mainly to diterpenoid lactones (andrographolides) from *Andrographis paniculata*. These compounds inhibit inflammatory mediators like NO production and COX-2 expression; they may also modulate immune responses via TLR4/NF-kappaB signaling pathway inhibition. Kan Jang has been shown in clinical studies to reduce symptom severity (sore throat, cough, runny nose), decrease disease progression rates in mild COVID-19 patients compared to placebo, shorten illness duration by about two days versus placebo for colds/flu-like illnesses[1][2][8]. It is registered as a traditional herbal medicine in several countries since 1997.

Brand names
Kan Jang
Other names
NergecovSwedish Herbal Institute Kan Jangcombination andrographis and eleutherocombination andrographis and Siberian ginseng
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on Kan Jang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kan Jang.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call